Therma Bright Receives Positive Notification from U.S. DHHS's Centers for Medicare & Medicaid (CMS)

Core Viewpoint - Therma Bright Inc. has received a positive notification from the U.S. Department of Health and Human Services' Centers for Medicare and Medicaid Services (CMS) regarding the pending permanent CPT® and HCPCS codes for its Venowave VW5 device, which is expected to enhance market opportunities for the company and its stakeholders [2][3][4]. Group 1: Company Update - The CMS is anticipated to provide permanent CPT® and HCPCS codes for the Venowave VW5 device in the coming days, which will cover ten health-related and CMS reimbursable indications [3][4]. - The ten indications include prevention and management of deep vein thrombosis (DVT), treatment of lymphedema, and enhancement of blood circulation, among others [4]. - The CDC estimates that over 900,000 U.S. citizens are affected by DVT and pulmonary embolism (PE) annually, indicating a significant market need for the Venowave device [4]. Group 2: Market Potential - The global market for deep vein thrombosis is projected to reach USD $1.26 billion by 2028 and USD $1.554 billion by 2032, highlighting substantial growth potential for Therma Bright's offerings [4]. - The anticipated CMS codes are expected to create a favorable environment for the company, its customers, and reseller partners, enhancing overall market presence [4]. Group 3: Leadership Statement - The CEO of Therma Bright expressed optimism regarding the upcoming confirmation from CMS and plans to announce the details of the permanent codes immediately upon receipt [5].